Zynga Announces Third Quarter 2017 Financial Results
Nov 07, 2017 21:07 pm UTC| Business
SAN FRANCISCO, Nov. 07, 2017 -- Zynga Inc. (Nasdaq:ZNGA) has released its third quarter 2017 financial results by posting management’s Q3 2017 Quarterly Earnings Letter on its website. Please visit...
Novavax Reports Third Quarter 2017 Financial Results
Nov 07, 2017 21:07 pm UTC| Business
GAITHERSBURG, Md., Nov. 07, 2017 -- Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the third quarter and nine months ended September 30, 2017. Third Quarter Achievements: Novavax initiated a...
ShotSpotter Reports Third Quarter 2017 Financial Results
Nov 07, 2017 21:07 pm UTC| Business
NEWARK, Calif., Nov. 07, 2017 -- ShotSpotter, Inc. (NASDAQ:SSTI), the leader in gunshot detection solutions that help law enforcement officials and security personnel identify, locate and deter gun violence, today...
Zillow Group Third Quarter 2017 Revenue Increased 25% Year-Over-Year
Nov 07, 2017 21:07 pm UTC| Business
Premier Agent Revenue increased 24% year-over-year to a record $197.1 million.More than 175 million average monthly unique users visited Zillow Group brands’ mobile apps and websites during the quarter, reaching an...
Full House Resorts Announces Solid Third Quarter Results
Nov 07, 2017 21:07 pm UTC| Business
- Net Revenues Increase 6.0% in the Third Quarter, Reflecting Growth in All of the Company's Business Segments - Two Growth Projects, the Rising Star RV Park and Silver Slipper Beach Complex,Completed in Third Quarter of...
TESARO Announces Third-Quarter 2017 Operating Results
Nov 07, 2017 21:07 pm UTC| Business
ZEJULA® was the most prescribed PARP inhibitor in U.S. with Q3 net sales of $39.4 millionPositive CHMP opinion issued for ZEJULA in E.U.; commercial launch anticipated to begin by year-endExpansion of niraparib development...
miRagen Therapeutics to Participate in Four Investor Conferences in November
Nov 07, 2017 21:07 pm UTC| Business
BOULDER, Colo., Nov. 07, 2017 -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S....
FDA Approval of Opdivo Injection Sparks Hope for Cancer Patients with Revolutionary Treatment Update